Resistance to Methoxymorpholinyl Doxorubicin in L1210 Cells
Author Information
Author(s): C. Geroni, E. Pesenti, M. Broggini, G. Belvedere, G. Tagliabue, M. D'Incalci, G. Pennella, M. Grandi
Primary Institution: Farmitalia Carlo Erba, Research Center; Istituto Di Richerche Farmacologiche 'Mario Negri'
Hypothesis
The study investigates the mechanism of resistance in murine L1210 leukaemia cells selected after treatment with methoxymorpholinyl doxorubicin.
Conclusion
L1210/MMRDX cells are specifically resistant to methoxymorpholinyl derivatives but sensitive to classic mdr-associated drugs.
Supporting Evidence
- L1210/MMRDX cells are resistant to all tested methoxymorpholinyl derivatives.
- The mechanism of resistance may be novel and specific for this class of drugs.
- L1210/MMRDX cells do not overexpress the mdrl gene.
- Resistance was stable for at least one year in vitro.
- Cells showed similar levels of DNA damage compared to sensitive cells.
Takeaway
Researchers found that certain cancer cells can become resistant to a new type of cancer drug, but they can still be treated with other drugs.
Methodology
The study involved isolating L1210/MMRDX cells through repeated in vitro treatments and characterizing their resistance patterns.
Limitations
The exact mechanism of resistance remains unidentified and may be specific to this class of drugs.
Participant Demographics
The study used murine (mouse) models, specifically DBA2 and CD2F1 adult female mice.
Want to read the original?
Access the complete publication on the publisher's website